Breaking Finance News

Juniper Pharmaceuticals Inc (NASDAQ:JNP) has been downgraded to Market Perform in a statement by Northland Securities earlier today.

Northland Securities has downgraded Juniper Pharmaceuticals Inc(NASDAQ:JNP) to Market Perform in a report released on 8/18/2016.

On 8/19/2016, H.C. Wainwright released a statement about Juniper Pharmaceuticals Inc(NASDAQ:JNP) raised the target price from $0.00 to $6.75 that indicated a possible upside of 0.17%.

Boasting a price of $5.91, Juniper Pharmaceuticals Inc (NASDAQ:JNP) traded 0.71% higher on the day. The last close is down 19.02% from the two hundred day moving average, compared with the S&P 500 which has decreased -0.01% over the same time period. Juniper Pharmaceuticals Inc has registered a 50-day moving average of $6.48 and 200-day moving average of $6.99. 15,805 shares of Juniper Pharmaceuticals Inc were exchanged, down from ann avg. volume of 27,998

Performance Chart:

Juniper Pharmaceuticals Inc (NASDAQ:JNP)

Juniper Pharmaceuticals Inc has a 52 week low of $4.30 and a 52 week high of $14.59. The company’s market cap is presently $0.0.

Also covering Juniper Pharmaceuticals Inc’s stock price target, a total of 3 brokers have released a ratings update on JNP. The 12-month target is $16.33 with 0 rating the stock a strong buy, two firms rating the company a buy, 0 analysts rating the stock a hold, 0 rating the company to underperform, and lastly 0 brokeragesrating the company as sell.

More About Juniper Pharmaceuticals Inc (NASDAQ:JNP)

Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, and JNP-0101 and JNP-0301.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *